Longer-term follow-up in the Vienna omega-3 psychosis prevention trial

Presentation First Author: 
G. Paul Amminger

Background: We have shown that a 12-week intervention with long-chain omega-3 polyunsaturated fatty acids (PUFAs) reduced the risk of progression to psychotic disorder in young people with subthreshold psychotic states for a 12-month period (Amminger et al., 2010, Arch Gen Psychiatry). Now we have completed a longer-term follow-up of this trial to determine the longer-term efficacy of omega-3-PUFAs in individuals at ultra-high risk (UHR) for psychosis. Methods: Randomized, double-blind trial of 1.2g/day omega-3 PUFAs or placebo in 81 UHR individuals. At longer-term follow-up participants, next of kin, and those involved in assessing outcomes or data entry were blind to group assignments. The primary outcome measure was transition to psychotic disorder. Secondary outcomes included functional, symptomatic, and vocational measures. Analyses were performed on an intent-to-treat basis. Results: The median duration of follow-up in the sample was 6.7 years. The transition to psychosis rate was 9.8% (4/41) in the omega-3 group and 40% (16/40) in the placebo group. The survival times were significantly different between the treatment groups, with a more rapid conversion time for the placebo group compared with the omega-3 group (log rank test: _2 = 9.84, p = 0.002). Functioning was significantly more improved in the omega-3 PUFA group than in the placebo group. Conclusions: A brief intervention with omega-3 PUFAs prevented psychosis for almost up to 7 years after baseline in the UHR individuals who participated in the trial.

Conference Name: 
Presentation Date: 
January, 2015
Additional Authors: 
Monika Schlögelhofer - Claudia Klier - Patrick McGorry - Miriam Schäfer
See other presentations in this session: